# Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

> **NCT05650216** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)

## Key facts

- **NCT ID:** NCT05650216
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-25
- **Primary completion:** 2023-12-25
- **Final completion:** 2024-12-25
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650216, "Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05650216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*